FDA 483 OBSERVATION · #96 OF 1,923 MOST-CITED
Lack of or inadequate final acceptance procedures
FDA cited this observation 301 times across 286 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Finished-device acceptance procedures were absent or inadequate, so devices could be released for distribution without confirming they passed the required final acceptance activities and record review.
Why FDA writes it — Final acceptance is the last gate before a device reaches a patient. Weak or missing procedures here mean a device can ship without the documented confirmation that it meets specifications and that its DHR was reviewed — exactly the failure the requirement exists to prevent.
- Establish procedures for finished-device acceptance to ensure each production run/lot/batch meets acceptance criteria.
- Hold devices in quarantine or otherwise control them until required acceptance activities are complete.
- Ensure finished devices are not released until the DHR is reviewed and the release is authorized by a designated individual, and the authorization is documented.
- Document the acceptance results and release decision.
- Release before final acceptance activities and DHR review are complete.
- No designated, documented release authorization, so accountability for release is unclear.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.4× the rate of the average FDA-cited firm (11.2% vs 7.8%), across 286 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for finished device acceptance have not been adequately established.
Procedures for finished device acceptance have not been adequately established.
Procedures for finished device acceptance have not been adequately established.
Procedures for finished device acceptance have not been adequately established.
Procedures for finished device acceptance have not been adequately established.
Procedures for finished device acceptance have not been established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →